Failure, page-8

Your idea of choosing only one drug regulatory agency as an either/or plan is puzzling. Large successful sponsors with reliable financing have the goal for their drugs to be approved on a global basis, by many regulatory agencies in many countries. Picking and choosing just one regulator who would consider Prana a sure winner is a losing proposition. There is no such regulatory agency.

Your talk of seeking approval by one drug regulator over another is extremely short-sighted. Instead of bad-mouthing in print a particular regulator you should realize that you are biting the hand that could feed you. Your idea of excluding the foremost drug regulator in the world is not very brilliant. Think of the future American $'s lost while Prana is sitting out decisions by other countries who are starting out the trial process from the beginning. Prana would need to cooperate with them and to communicate with their shareholders to keep the company in existence.

If Prana's investigative drugs would meet the needs of biopharmas who are looking to add promising therapeutics to their large pipelines, approvals might be hastened with the help of experienced administrators. There are no potential partners in sight...no licensing plans.